Design, synthesis and pharmacological characterization of the first photoswitchable small-molecule agonist for the Atypical Chemokine Receptor 3

Sophie Bérenger,Justyna M. Adamska,Francesca Deflorian,Chris de Graaf,Christie B. Palmer,Martyna Szpakowska,Andy Chevigné,Iwan J. P. de Esch,Barbara Zarzycka,Henry F. Vischer,Maikel Wijtmans,Rob Leurs

DOI: https://doi.org/10.1101/2024.03.20.585914

2024-03-25

Abstract:Photopharmacology offers the promise of optical modulation of cellular signaling in a spatially and temporally controlled fashion with light-sensitive molecules. This study presents the first small-molecule photoswitchable agonist for an atypical G protein-coupled receptor (GPCR), the atypical chemokine receptor 3 (ACKR3). Inspired by a known benzylpiperidine-based ACKR3 agonist scaffold, 12 photoswitchable azobenzene-containing analogs were synthesized and characterized for their interaction with ACKR3. After analysis of Structure-Photochemistry and Structure-Affinity Relationships (SAR), compound was selected as the best photoswitchable ACKR3 agonist in the series. Compound can be effectively switched from its thermodynamically stable state to the less active -isomer with a PhotoStationary State of 96 %. The thermodynamically less stable only slowly switches back to the state (t = 15 days), and binds and activates ACKR3 at 10-fold lower concentrations compared to its -isomer. Compound demonstrates selectivity for ACKR3 within in a panel of chemokine receptors. Using the recently published ACKR3 cryo-EM structures in computational studies, a binding mode for is proposed and is perfectly in line with the observed SAR and the loss of interaction with ACKR3 upon photoswitching. ACKR3 agonist (VUF25471) is the first photoswitchable ligand for an atypical GPCR and will be a useful tool to investigate the role of ACKR3 in biological settings.

Pharmacology and Toxicology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop the first light - controlled small - molecule agonist for atypical chemokine receptor 3 (ACKR3). Specifically, the researchers aim to design, synthesize and characterize a series of small - molecule compounds containing photosensitive azobenzene groups in order to achieve light - controlled activation of ACKR3. These compounds can be converted from the thermodynamically stable trans - state to the less active cis - isomer under illumination, thereby allowing precise control of the cell signaling process in time and space. Through this method, the researchers hope to provide a powerful tool for exploring the role of ACKR3 in the biological environment.

The key compound 3e mentioned in the paper was selected as the best light - controlled ACKR3 agonist. It can be effectively converted from the trans - state to the cis - state under illumination conditions, and this conversion is highly reversible. In addition, the selectivity of 3e for ACKR3 has also been verified among a series of chemokine receptors, showing its potential as a research tool.

In summary, this study not only solves the problem of how to design and synthesize effective light - controlled small - molecule agonists, but also provides new means for further understanding the function of ACKR3 and its role in diseases.